A phase II study of S-1 monotherapy as second-line treatment for advanced non-small cell lung cancer

Totani, Yoshitaka; Saito, Yuji; Hayashi, Masamichi; Tada, Takashi; Kohashi, Yasuo; Mieno, Yuki; Kato, Atsushi; Imizu, Hiromi; Yoneda, Yukiko; Hoshino, Tyuji; Uchiyama, Yoshiyasu; Takeuchi, Yasuo; Okazawa, Mitsushi; Sakakibara, Hiroki

doi:10.1007/s00280-009-0981-1

Cited by 33 publications

(27 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the monotherapy group in the present study, OS following S-1 therapy was lower compared with those in previous clinical trials (2,3,18). This may be due to the inclusion of patients with second-, or a later, line of S-1 monotherapy in the present study.…”

Section: Discussioncontrasting

confidence: 63%

See 1 more Smart Citation

S-1-containing chemotherapy for patients with non-small-cell lung cancer: A population-based observational study by the Ibaraki thoracic integrative (POSITIVE) research group

Inagaki

Shinohara

Kaburagi

et al. 2016

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 63%

“…S-1 was shown to produce an active response as a single agent for metastatic NSCLC with minimal toxicity (2,3,18). Kawahara et al (2) reported that S-1 monotherapy had an RR of 22%, median response duration, 3.4 months, and OS of 22%.…”

Section: Discussionmentioning

confidence: 99%

S-1-containing chemotherapy for patients with non-small-cell lung cancer: A population-based observational study by the Ibaraki thoracic integrative (POSITIVE) research group

Inagaki

Shinohara

Kaburagi

et al. 2016

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…Thus, extensive efforts are under way to examine the effects of the combination of bevacizumab and chemotherapy during the maintenance phase of treatment for advanced nonsquamous NSCLC. On the basis of the low level of toxicity accumulation for S-1, 21 we explored the efficacy and feasibility of continued maintenance therapy with S-1 and bevacizumab in the current study. The favorable tolerability profile of maintenance with S-1 and bevacizumab after induction therapy with S-1, carboplatin, and bevacizumab is reflected in out observation that 60% of patients were able to continue on S-1 and bevacizumab for a median of 4 cycles (range, 1-18 cycles).…”

Section: Discussionmentioning

confidence: 99%

“…Patients received S-1 orally at a dose of 80 mg/m 2 per day on days 1 through 14 as well as carboplatin at a dose calculated to produce an area under the concentration-time curve of 5 mg mL 21 per minute and bevacizumab at a dose of 15 mg/kg as an intravenous infusion on day 1. The combination therapy was repeated every 21 days for up to 4 to 6 cycles unless there was evidence of disease progression or intolerance of the study treatment.…”

Section: Study Design and Treatmentmentioning

confidence: 99%

Phase 2 study of S‐1 and carboplatin plus bevacizumab followed by maintenance S‐1 and bevacizumab for chemotherapy‐naive patients with advanced nonsquamous non–small cell lung cancer

Urata

Okamoto

Takeda

et al. 2013

Cancer

View full text Add to dashboard Cite

BACKGROUND:A previous phase 3 trial demonstrated noninferiority in terms of overall survival for combined S-1 (an oral fluoropyrimidine) and carboplatin compared with combined paclitaxel and carboplatin as first-line treatment for advanced non-small cell lung cancer (NSCLC). In the current study, the authors evaluated the efficacy and safety of combined S-1, carboplatin, and bevacizumab followed by maintenance with S-1 and bevacizumab in chemotherapy-naive patients with advanced nonsquamous NSCLC. METHODS: Patients received carboplatin (area under the concentration-time curve, 5 mg mL 21 per minute) and bevacizumab (15 mg/kg) on day 1 plus oral S-1 (80 mg/m 2 per day) on days 1 through 14 every 21 days for up to 6 cycles. For patients without disease progression, S-1 and bevacizumab were continued until disease progression or unacceptable toxicity developed. RESULTS: Forty-eight patients were enrolled in the phase 2 study; of these, 35 patients (72.9%) completed at least 4 cycles. Most toxicities of grade 3 were hematologic, and no increase in relative incidence associated with maintenance with S-1 and bevacizumab was observed. The objective response rate was 54.2% (95% confidence interval, 39.2%-68.6%), and the median progression-free survival was 6.8 months (95% confidence interval, 4.3-8.2 months). CONCLUSIONS: The regimen of combined S-1, carboplatin, and bevacizumab followed by maintenance with S-1 and bevacizumab was active and feasible as first-line treatment for advanced nonsquamous NSCLC. Cancer 2013;119:2275-81. INTRODUCTIONLung cancer is the leading cause of death related to cancer worldwide, with non-small cell lung cancer (NSCLC) accounting for 85% of lung cancer cases. 1 For individuals with advanced or metastatic NSCLC, platinum-based chemotherapy is the mainstay of first-line treatment 2,3 on the basis of the moderate improvement in survival and quality of life it affords compared with best supportive care alone. 4 A phase 3 study, the Eastern Cooperative Oncology Group (ECOG) E4599 trial, demonstrated that bevacizumab, a humanized monoclonal antibody specific for vascular endothelial growth factor, 5 given with paclitaxel and carboplatin resulted in significant improvements in the overall response rate (ORR), progression-free survival (PFS), and overall survival (OS) compared with paclitaxel and carboplatin alone in individuals with advanced nonsquamous NSCLC. 6 A Japanese phase 2 study also indicated that bevacizumab in combination with paclitaxel and carboplatin improved the ORR and PFS compared with paclitaxel and carboplatin alone. 7 In a confirmatory phase 3 study (the Avastin in Lung [AVAiL] trial), the addition of bevacizumab to cisplatin and gemcitabine resulted in a significant improvements in the ORR and PFS. 8,9 These observations provide a rationale for combining bevacizumab with platinum-doublet chemotherapy in individuals with advanced nonsquamous NSCLC.

show abstract

“…Several phase II trials or retrospective analyses of S-1 monotherapy as 2 nd or further lines have been reported for patients with NSCLC, who were generally younger than 75 years of age [5][6][7][8][9][10][11]. Reported average RR and PFS were 5.7-26.7% and 43 days to 4.2 months, respectively.…”

Section: Discussionmentioning

confidence: 99%

Delayed onset, Long-term Efficacy of S-1 Monotherapy for an Elderly Patient with Squamous Cell Lung Cancer

Kanaji

Nanki²,

Tadokoro³

et al. 2014

Chemotherapy (Los Angel)

View full text Add to dashboard Cite

The efficacy of S-1 monotherapy as a 2 nd -line regimen for elderly patients with non-small cell lung cancer (NSCLC) has not been reported, nor has delayed onset regression after temporary progression of tumor during an identified therapeutic regimen. Here we report a 78-year-old man was diagnosed with T3N3M1b (BRA), stage IV squamous cell lung cancer. His primary lesion progressed after whole brain irradiation and 4 cycles of 1 st -line chemotherapy with docetaxel. S-1 monotherapy was prescribed as the 2 nd -line treatment. Each cycle of chemotherapy comprised 14 days of S-1 (40 mg, twice daily) followed by 14 drug-free days. After 6 months of S-1 monotherapy, primary and metastatic lesions had started regressing significantly. He continued S-1 monotherapy for 19 months (20 cycles) with a comfortable daily life until reaching progressive disease. S-1 monotherapy as a 2 nd -line could be a therapeutic option for elderly patients with NSCLC. Moreover, long-term use of S-1 might be worth trying if adverse events and tumor growth are tolerable and other anti-cancer drugs are not applicable, because S-1 has a potential for delayed onset efficacy.

show abstract

A phase II study of S-1 monotherapy as second-line treatment for advanced non-small cell lung cancer

Abstract: S-1 is an active and well-tolerated monotherapy for second-line treatment of advanced NSCLC.

Cited by 33 publications

References 15 publications

S-1-containing chemotherapy for patients with non-small-cell lung cancer: A population-based observational study by the Ibaraki thoracic integrative (POSITIVE) research group

S-1-containing chemotherapy for patients with non-small-cell lung cancer: A population-based observational study by the Ibaraki thoracic integrative (POSITIVE) research group

Phase 2 study of S‐1 and carboplatin plus bevacizumab followed by maintenance S‐1 and bevacizumab for chemotherapy‐naive patients with advanced nonsquamous non–small cell lung cancer

Delayed onset, Long-term Efficacy of S-1 Monotherapy for an Elderly Patient with Squamous Cell Lung Cancer

Contact Info

Product

Resources

About